Cargando…

The effect of domiciliary high flow nasal cannula treatment on dyspnea and walking distance in patients with interstitial lung disease – A pilot study

INTRODUCTION: Interstitial Lung Diseases (ILD) affect the lung parenchyma and are often complicated by respiratory failure (RF) and impaired physical activity. High Flow Nasal Cannula (HFNC) has proved effective in other disease entities with RF. The aim of this study is to investigate the effect of...

Descripción completa

Detalles Bibliográficos
Autores principales: Weinreich, Ulla Møller, Burchardt, Charlotte, Huremovic, Jasmina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9661555/
https://www.ncbi.nlm.nih.gov/pubmed/36366859
http://dx.doi.org/10.1177/14799731221137085
_version_ 1784830503002570752
author Weinreich, Ulla Møller
Burchardt, Charlotte
Huremovic, Jasmina
author_facet Weinreich, Ulla Møller
Burchardt, Charlotte
Huremovic, Jasmina
author_sort Weinreich, Ulla Møller
collection PubMed
description INTRODUCTION: Interstitial Lung Diseases (ILD) affect the lung parenchyma and are often complicated by respiratory failure (RF) and impaired physical activity. High Flow Nasal Cannula (HFNC) has proved effective in other disease entities with RF. The aim of this study is to investigate the effect of domiciliary HFNC in ILD on dyspnea and walking distance. METHODS: A 6 weeks cross-over study with domiciliary HFNC-treatment/6 weeks’ observation in ILD-patients requiring ambulatory oxygen therapy or with newly prescribed (within 12 months) long term oxygen therapy. Patients were advised to use HFNC 8 h/day, recommended night-time use. Body phletysmography; 6-min walk test (6MWT) including BORG-score, oxygen saturation (SO(2)) at start, minimum SO(2) and time to recovery after 6MWT; arterial blood gasses; modified Medical Research Council (mMRC)-score; quality of life, by the St George Respiratory Questionnaire (SGRQ) and QoS, by the Richards-Campbell Sleep Questionnaire (RCSQ) were investigated at baseline; six weeks and 12 weeks. RESULTS: 10 patients were included; one later withdrew consent. Patients used HFNC between 8-<1 h/day. There were no differences in lung function; blood gasses; SGRQ or RCSQ over the observational period). Walking distance improved significantly (393–441 m p = 0.049) as did time to recovery (3.4–2-2 min, p = 0.001). When correcting for HFNC use (hours/day) significant improvement was also seen in mMRC-score (p = 0.035) and minimum saturation during 6MWT (p = 0.01). CONCLUSION: Despite a very heterogenous group and no effect on quality of life and -sleep, the study indicates an improvement in dyspnea and physical ability of HFNC in ILD patients.
format Online
Article
Text
id pubmed-9661555
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-96615552022-11-15 The effect of domiciliary high flow nasal cannula treatment on dyspnea and walking distance in patients with interstitial lung disease – A pilot study Weinreich, Ulla Møller Burchardt, Charlotte Huremovic, Jasmina Chron Respir Dis Original Paper INTRODUCTION: Interstitial Lung Diseases (ILD) affect the lung parenchyma and are often complicated by respiratory failure (RF) and impaired physical activity. High Flow Nasal Cannula (HFNC) has proved effective in other disease entities with RF. The aim of this study is to investigate the effect of domiciliary HFNC in ILD on dyspnea and walking distance. METHODS: A 6 weeks cross-over study with domiciliary HFNC-treatment/6 weeks’ observation in ILD-patients requiring ambulatory oxygen therapy or with newly prescribed (within 12 months) long term oxygen therapy. Patients were advised to use HFNC 8 h/day, recommended night-time use. Body phletysmography; 6-min walk test (6MWT) including BORG-score, oxygen saturation (SO(2)) at start, minimum SO(2) and time to recovery after 6MWT; arterial blood gasses; modified Medical Research Council (mMRC)-score; quality of life, by the St George Respiratory Questionnaire (SGRQ) and QoS, by the Richards-Campbell Sleep Questionnaire (RCSQ) were investigated at baseline; six weeks and 12 weeks. RESULTS: 10 patients were included; one later withdrew consent. Patients used HFNC between 8-<1 h/day. There were no differences in lung function; blood gasses; SGRQ or RCSQ over the observational period). Walking distance improved significantly (393–441 m p = 0.049) as did time to recovery (3.4–2-2 min, p = 0.001). When correcting for HFNC use (hours/day) significant improvement was also seen in mMRC-score (p = 0.035) and minimum saturation during 6MWT (p = 0.01). CONCLUSION: Despite a very heterogenous group and no effect on quality of life and -sleep, the study indicates an improvement in dyspnea and physical ability of HFNC in ILD patients. SAGE Publications 2022-11-10 /pmc/articles/PMC9661555/ /pubmed/36366859 http://dx.doi.org/10.1177/14799731221137085 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Paper
Weinreich, Ulla Møller
Burchardt, Charlotte
Huremovic, Jasmina
The effect of domiciliary high flow nasal cannula treatment on dyspnea and walking distance in patients with interstitial lung disease – A pilot study
title The effect of domiciliary high flow nasal cannula treatment on dyspnea and walking distance in patients with interstitial lung disease – A pilot study
title_full The effect of domiciliary high flow nasal cannula treatment on dyspnea and walking distance in patients with interstitial lung disease – A pilot study
title_fullStr The effect of domiciliary high flow nasal cannula treatment on dyspnea and walking distance in patients with interstitial lung disease – A pilot study
title_full_unstemmed The effect of domiciliary high flow nasal cannula treatment on dyspnea and walking distance in patients with interstitial lung disease – A pilot study
title_short The effect of domiciliary high flow nasal cannula treatment on dyspnea and walking distance in patients with interstitial lung disease – A pilot study
title_sort effect of domiciliary high flow nasal cannula treatment on dyspnea and walking distance in patients with interstitial lung disease – a pilot study
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9661555/
https://www.ncbi.nlm.nih.gov/pubmed/36366859
http://dx.doi.org/10.1177/14799731221137085
work_keys_str_mv AT weinreichullamøller theeffectofdomiciliaryhighflownasalcannulatreatmentondyspneaandwalkingdistanceinpatientswithinterstitiallungdiseaseapilotstudy
AT burchardtcharlotte theeffectofdomiciliaryhighflownasalcannulatreatmentondyspneaandwalkingdistanceinpatientswithinterstitiallungdiseaseapilotstudy
AT huremovicjasmina theeffectofdomiciliaryhighflownasalcannulatreatmentondyspneaandwalkingdistanceinpatientswithinterstitiallungdiseaseapilotstudy
AT weinreichullamøller effectofdomiciliaryhighflownasalcannulatreatmentondyspneaandwalkingdistanceinpatientswithinterstitiallungdiseaseapilotstudy
AT burchardtcharlotte effectofdomiciliaryhighflownasalcannulatreatmentondyspneaandwalkingdistanceinpatientswithinterstitiallungdiseaseapilotstudy
AT huremovicjasmina effectofdomiciliaryhighflownasalcannulatreatmentondyspneaandwalkingdistanceinpatientswithinterstitiallungdiseaseapilotstudy